Subscribe to our Newsletters !!

    Placebo

    Study: Anti-microRNA sedate essentially lessens miR-92a levels in human peripheral blood

    A single intravenous dose of MRG-110, an anti-microRNA drug, significantly reduced miR-92a levels from the blood of healthy humans. “According to documented, promising therapeutic possible, locked nucleic acid (LNA)-based anti-miR-92a was further developed and tested in a first in human analysis,” said Stefanie Dimmeler, PhD, Goethe University, Frankfurt, Germany and coauthors. “MRG-110 caused de-repression of

    Scientists study misleading impact in nausea therapy at the molecular level

    The molecular bases of the placebo effect are poorly understood. A team headed by Ludwig-Maximilians-Universitaet (LMU) in Munich researcher Karin Meissner has now studied the phenomenon in the context of nausea, and identified specific proteins that correlate with its positive impact. The placebo effect seems to work wonders. In certain cases, administration of a’drug’ to

    Trial ALS drug shows potential to drag out patient endurance

    An experimental medicine that was recently shown to slow the progression of the neurodegenerative disease amyotrophic lateral sclerosis (ALS), or Lou Gehrig’s disease, has now demonstrated the capacity to also prolong patient survival. The findings come from a clinical trial conducted by investigators at the Sean M. Healey & AMG Center for ALS at Massachusetts

    Polypill in addition to headache medicine and polypill alone reduced cardiovascular sickness hazard

    A single, daily pill combining blood pressure and cholesterol medications, as well as the addition of a daily dose of aspirin, reduced cardiovascular disease events in people at risk for heart disease, according to late-breaking study presented today in a late-breaking clinical trial presentation at the American Heart Association’s Scientific Sessions 2020. The virtual conference,

    New upkeep treatment for AML shows solid advantage for patients

    Patients with acute myeloid leukemia (AML), the most common form of leukemia in adults, that has gone into remission following initial chemotherapy remain in remission longer and have improved overall survival when they are given a pill form of the cancer drug azacitidine as a maintenance therapy, based on a randomized, international phase 3 clinical

    Study assesses stem cells’ capacity to forestall significant reason for death in preterm newborn

    A phase 2 clinical trial whose results were published today in STEM CELLS Translational Medicine might point to a way to conquer bronchopulmonary dysplasia (BPD), a significant cause of death in preterm infants. The study, conducted by researchers at Samsung Medical Center, Sungkyunkwan University and Asan Medical Center Children’s Hospital in Seoul, evaluates the efficacy

    Study reveals insight into the capacity of CBD to decrease pain

    It’s been hailed as a wonder drug and it’s certainly creating wonder profits. By some estimates, the Cannabidiol (or CBD) market could be worth $20 billion dollars by 2024. While consumers tout its effectiveness in pain relief, up until now there has been limited experimental human research on the true effectiveness of the medication. But

    FDA supports new medication for therapy of adults with chronic kidney infection

    Today, the U.S. Food and Drug Administration accepted Farxiga (dapagliflozin) oral tablets to decrease the risk of kidney function decline, kidney failure, cardiovascular death and hospitalization for heart failure in adults with chronic kidney disease who are at risk of disease progression. Chronic kidney disease occurs when the kidneys are damaged and can’t filter blood

    Study proposes expected role for probiotics in forestalling respiratory infections

    Daily probiotic use was associated with fewer upper respiratory symptoms in overweight and older people, according to a study which suggests a potential role for probiotics in preventing respiratory infections. Researchers re-analyzed detailed daily diaries of 220 patients who engaged in a previous double-blind placebo-controlled study on probiotics and weight loss. Reviewing the entries for